Loading…
RLYB
Rallybio Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 75120L209
$16.40+0.52%Price as of Oct 23, 00:53 UTC · updated once a day, after the close
At a glance
Rallybio Corp (RLYB) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in New Haven, United States and has 7 employees. The company is worth $87.13M and trades at 2.0x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $858K in fiscal 2025, up 34.9% from the year before. It reported a net loss of $8.98M. The share price is 6.7% below its 52-week high of $17.57. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Andreas Halvorsen (Viking Global Investors), at $8.39M. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $87.13M
- P/E
- 2.0x
- Forward P/E
- —
- P/B
- 0.9x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $8.01
- ROE
- 64.86%
- Profit margin
- 7051.24%
- Revenue growth
- —
- Beta
- -0.71
- 52-week high
- $17.57
- 52-week low
- $3.67
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -84.2% over 5Y.
today you would have $114.01▼ -88.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $5.49 | $7.68 | $19.12 | $52.56 | $76.32 | |
| P/S | — | 33.8x | 62.8x | — | — | — |
| P/B | 0.9x | 0.5x | 0.6x | 0.9x | 1.5x | 1.7x |
| EPS | -$1.59 | -$10.61 | -$14.72 | -$16.72 | -$14.72 | |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$56.65
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $4.52 | — | 0.8x | 0.00% | -95.58% | $87.42M |
| INOInovio Pharmaceuticals Inc | $0.84 | — | 15.8x | 0.00% | -409.87% | $86.74M |
| CNXUConexeu Sciences Inc. | $3.06 | — | 14.3x | 0.00% | -332.94% | $86.31M |
| MISTMilestone Pharmaceuticals Inc. |
About the company
- 7
- New Haven, United States